Cagrilintide

Cagrilintide is a long-acting amylin analog used off-label for weight loss and appetite control, though its primary clinical evidence base remains anchored in Type 2 Diabetes management. Community users typically run doses around 250 mcg, while clinician-tier protocols suggest a range of 250 mcg to 2.4 mg administered weekly via subcutaneous injection. Users occasionally report nausea, gastrointestinal distress, and injection-site reactions. Readers should note that the off-label evidence base for this peptide is significantly thinner than current discourse suggests, and there is no insurance pathway for coverage outside of its approved indication for Type 2 Diabetes.

Half-life~7 days

Data last updated

ClinicalResearchDepthClinicalResearchEfficacyClinicalResearchSideEffectsAnecdotalEfficacyAnecdotalSideEffectsPrice3.42.83.23.73.04.0

Research Evidence

Evidence shape

Cagrilintide holds moderate clinical evidence, primarily supported by human studies focused on Type 2 diabetes and weight management. While the research spans 14 distinct indications, the breadth of data remains thin, with only one trial currently featuring published results despite 39 registered studies. The majority of these investigations are either active, recruiting, or represent long-tail exploratory research, signaling that while the peptide has reached Phase 3 trial status, the clinical record is still in its early stages of public verification.

Depthhow much
40 registered trials
21 completed · 1 with posted results · 19 recruiting / active · combined n=92
Breadthhow many areas
14 indications mapped
1 with results · 12 thin / exploratory · 1 animal-only · 7 single-trial long-tail
Qualityhow rigorous
Highest tier: Phase 3
1 blinded with results · AE table from NCT04982575 · 10 linked publications on registered trials
Breadth and depth56 rows captured
Human
direct clinical signal
49
Animal
translational support
2
In vitro
mechanistic support
5
HighMediumLow

Anecdotal efficacy

Cagrilintide side effects

Clinical research side effects

Anecdotal side effects

Price

Full buying guide →
1
Nextgenpeps
USA
10 mg
$1.32
$0.13/mg
2
Bio Hack London
GB
100 mg
$79.19
$0.792/mg
3
Nurev Peptides
--
10 mg
$13.99
$1.4/mg
4
BOC Peptide
--
100 mg×10
$160.00
$1.6/mg
5
Adaptog Research
GB
1010 mg
$1,620.78
$1.61/mg
6
Mrbeetoe
--
50 mg
$110.00
$2.2/mg

price offers can be sorted by column

1-6 of 176

Cagrilintide dosing & protocol

How Cagrilintide is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols · n = 29
Typical dose
2.4 mg600 µg – 2.4 mg
typical
0
2 mg
4 mg
6 mg
distribution of 16 reported doses · darker = more
Frequency
weekly
Route
subQ

In clinical trials, cagrilintide is given subcutaneously at a typical dose of 2.4 mg once weekly, with studied doses ranging from 0.9 mg to 2.4 mg per week.

29 sources
Clinician practice
Doctor & published-protocol guidance · n = 3
Starting dose
250 µg250 µg – 2.4 mg
start
0
2 mg
4 mg
6 mg
distribution of 3 reported doses · darker = more
By reported cadence· tap a row to filter the chart
Frequency
weekly
Route
subQ

Clinician protocols dose 250 µg–2.4 mg weekly subQ (3 sources).

3 sources
Anecdotal
Community-reported real-world use · n = 33
Typical dose
250 µg12.5 µg – 6 mg
typical
0
2 mg
4 mg
6 mg
distribution of 37 reported doses · darker = more
Frequency
unspecified
Route
subQ

Doses reported across 53 accounts range from 300 mcg to 15 mg subcutaneously, with no consistent cadence established; a handful of sources note weekly administration, at 1.3 mg and 2.4 mg per week.

33 sources

Related peptides

SemaglutideTirzepatideRetatrutideSurvodutideAOD-9604OrforglipronLiraglutideExenatideTesamorelinEloralintideMazdutideTesofensine